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ABSTRACT 
Background: Chronic lymphocytic leukemia (CLL) is characterized by accumulation of B cells in blood, 
lymphoid tissues and bone marrow. Addition of rituximab to CLL chemotherapy regimens has been associated 
with improved survival. The aim of this study was to establish efficacy and safety of Zytux™ in comparison to 
MabThera® in treatment of CLL. 
Materials and Methods: Seventy CLL patients who met the criteria for entering the study were randomized 
into two groups (35 patients in each group). Both groups received Fludarabine and Cyclophosphamide plus 
Rituximab as part of the FCR regimen. Group A was treated with Zytux™, and group B was treated with 
MabThera®. A non-inferiority margin of 20% for the primary outcome was defined to examine the similarity 
between Zytux™ and MabThera®. 
Results: Baseline demographic characteristics showed no statistically significant difference between the two 
groups.  
The two treatment groups were comparable in terms of laboratory and clinical findings, cellular index changes 
and CD (5, 19, 20 and 23) counts during therapy cycles and at the end of the treatment period. Regarding 
safety results, Zytux™ demonstrated a similar profile of adverse reactions in comparison to MabThera®. 
Moreover, the overall response rate was 88% and 89% for Zytux™ and MabThera®, respectively (CI -0.17, 
0.18). 
Conclusion: Results showed non-inferiority of Zytux™ in terms of efficacy and adverse events as a biosimilar 
version of MabThera®. 
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INTRODUCTION 
   Chronic lymphocytic leukemia (CLL) is the most 
prevalent form of chronic leukemia 1,2. The course 
of the disease generally contains multiple relapses 
and remissions 3. Current therapies are more likely 
to lessen the symptoms, disease progression or the 
frequency of relapses rather than cure, and 
currently available chemotherapy regimens need to 
be reinforced with more efficacious novel 
therapeutic agents 4-8.   
Monoclonal antibodies including rituximab (that 
binds to CD20 antigen on B-cell surface) are among 
the most effective treatment options 9,10. In 
addition, a number of studies have revealed that 
the survival and cure rates were significantly higher 
in patients treated with Rituximab, Fludarabine and 
Cyclophosphamide (FCR) compared to Fludarabine 
and Cyclophosphamide (FC) alone and, among 
other various chemotherapy regimens, FCR is 
widely accepted as standard plan for treatment of 
CLL 11-13. Based on these findings, rituximab was 
approved for treatment of CLL at 500 mg/m2 in 
combination with FC regimen. 
Monoclonal antibodies development requires 
multiple complex processes, and therefore these 
high-tech products are generally high-priced14. In 
order to provide opportunities to improve 
healthcare access, expand outcomes and reduce 
costs, biosimilar agents (molecules similar in 
structure, function, and safety to the original 
biological drugs) are introduced15. 
 
Zytux™ (Rituximab, AryoGen Pharmed) is the 
intended biosimilar product of MabThera® 
(Rituximab, Roche) which has exhibited acceptable 
compatibility profile during non-clinical phase. In 
order to show biosimilarity of Zytux™ to MabThera®, 
we have conducted a double-blind, randomized, 
non-inferiority clinical trial in CLL patients to 
compare the efficacy and safety of the two 
products.  
 
MATERIALS AND METHODS 
Design 
This trial was designed with two parallel arms and 
random group assignment. The comparator 
medicine and the control were Zytux™ and 
MabThera®, respectively. Patients also received 
Fludarabine and Cyclophosphamide as part of the 
FCR regimen. Eligible patients were randomly 
assigned into two groups using a permuted-block 
randomization method at the end of the patients’ 
first visit, and the assessors were blinded to brand 
of rituximab administered (double- blind trial). A 
non-inferiority margin of 20% for primary outcome 
was selected by principal investigator (licensed 
oncologist) as an acceptable estimated difference 
between the comparator and the control. All 
procedures performed in studies involving human 
participants were in complete accordance with the 
1964 Helsinki declaration and its later amendments 
and/or comparable ethical standards. The trial was 
approved by the ethics committee of Iranian Blood 
Transfusion Organization (IBTO) and was registered 
at Iranian Registry of Clinical Trials 
(IRCT201305296302N5). 
 
Patients 
The inclusion criteria were age of 18 years or more, 
diagnosis of untreated or recurrent B-CLL with 
indication for therapy (according to the National 
Cancer Institute Working Group diagnostic criteria), 
positive CD20 marker and Binet stage of B or C. 
Patients were excluded from study if they had one 
or more of following conditions: pregnancy or 
lactation, severe autoimmune hemolytic anemia, 
current active infections or underlying diseases such 
as Hepatitis B or C, HIV, severe cardiac or 
pulmonary disorders, recent myocardial infarction, 
uncontrolled hypertension and epilepsy, diabetes 
mellitus, elevated hepatic enzyme levels (more than 
2 fold ULN), serum creatinine more than 2 mg/dl, 
known hypersensitivity with anaphylactic reaction 
to chimeric monoclonal antibodies or any of study 
drugs. 
 
Procedure 
Demographic information, medical history, physical 
examination, required lab tests (including CBC with 
differential, liver function tests, renal function tests, 
flow cytometric evaluation of CD counts and 
hemoglobin), especially disease staging were 
assessed during this visit. Subsequent visits were 
scheduled for chemotherapy administration; all 
efficacy and safety measures were then reassessed 
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at each visit prior administration of chemotherapy 
regimen. 
All patients received combination therapy of 
Fludarabine (25 mg/m2 IV infusion, on 2nd to 4th day 
of each cycle), Cyclophosphamide (250 mg/m2 IV 
infusion, on 2nd to 4th day of each cycles) and 
Rituximab (375 mg/m2 at first cycle and 500 mg/m2 
at all subsequent cycles, IV infusion on day 1 of each 
cycle) as standard 28-day cycles. Group A was 
treated with Zytux™ and group B was administered 
MabThera®. It should be noted that due to took four 
courses of therapy during research protocol and 
two additional courses out of project. 
 
Outcomes 
The primary outcome was overall response rate 
(ORR) which is defined by the sum of complete 
response rate (CR) and partial response rate (PR). 
These were assessed following completion of 
scheduled chemo-immunotherapy cycles based on 
IWCLL (International Workshop on CLL) response 
criteria as shown in  
Table 1 16. Secondary outcome measures were B-
cell specific markers and safety profile (the 
comparison of complications and adverse reactions) 
which were evaluated during and upon completion 
of scheduled chemotherapy cycles. 
 
Table 1: Definition of complete and partial response 
Parameter Complete response 
(all required) 
Partial response 
Lymphocytes ≤4000/µl ≥50%↓a 
Lymph Nodes No palpable disease 
(LN<1.5cm) 
≥50%↓ a 
Splenomegaly None ≥50%↓ a 
Hepatomegaly None ≥50%↓ a 
Constitutional 
symptoms 
None Variable 
Neutrophils ≥1,500/µl ≥1,500/µl or ≥50% 
improvement b 
Platelets >100,000/µl >100,000/µl or ≥50% 
improvement b 
Hemoglobin >11g/dl 
(untransfused) 
>11g/dl or ≥50% 
improvement b 
a: must achieve at least two of parameters 
b: must achieve at least one parameter 
 
Statistical analysis 
For Non-inferiority inference, normal approximation 
test was used to compare overall response as 
primary outcome between the two groups. Forest 
plot compared statistical confidence interval and 
clinical distance graphically. Next, generalized 
estimating equation models were applied to analyze 
antigenic outcomes according to time-to-event 
data. Frequency and type of adverse reactions were 
measured by descriptive tools. Laboratory 
parameters and baseline characteristics were 
analyzed by Mann-Whitney and t-test. Per-protocol-
analysis was applied to analysis ideal patients. All 
statistical analyses were conducted using STATA 11. 
All p-values less than or equal to 0.05 were 
considered statistically significant. 
 
RESULTS 
Patients 
A total of 82 patients were screened and 70 eligible 
patients were enrolled. As shown in Figure 1, 14 of 
the 70 patients randomized did not receive 
allocated intervention: 7 discontinued treatment (5 
in Zytux™ arm and 2 in MabThera® arm), 2 expired 
(both in MabThera® arm) and 5 were lost to follow-
up (3 in Zytux™ arm and 2 in MabThera® arm).  
 
 
 
Figure 1. Trial Profile 
 
 
82 patients were 
included 
70 patientsincluded 
signed informed 
consent then enrolled 
and randomised 
Arm A:  
35 patients received 
FC + Zytux™ 
27 patients completed the 
trial and 25 patients 
results were analysed  
8 patients excluded  
Arm B:  
35 patients received 
®FC + MabThera 
29 patients 
completed the trial 
and 26 patients  
results were analysed  
6 patients excluded 
12 patients did not fulfilled 
the inclusion criteria 
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Baseline information 
Baseline and demographic data analysis 
demonstrated adequate homogeneity between 
treatment arms. The mean±SD of age was 
57.94±8.44 and 59.24±8.16 years for Zytux™ and 
MabThera® groups, respectively. Majority of 
patients were males (28/7 male/female in Zytux™ 
group and 29/6 male/female for MabThera® group). 
Baseline lab tests including WBCs, Plt, Hb, liver and 
renal function tests were comparable among 
treatment groups. Demographic information is 
summarized in Table 2. The difference between 
baseline information was considered insignificant.  
Moreover, disease staging assessment revealed that 
lymphadenopathy was present in 25 patients in 
Zytux™ arm and 26 patients in MabThera® arm (p-
value=0.94), splenomegaly was present in 21 
patients in Zytux™ arm and 25 patients in 
MabThera® arm (p-value=0.27) and hepatomegaly 
was present in 3 patients in Zytux™ arm and 5 
patients in MabThera® arm (p-value=0.43). 
 
Table 2: Baseline demographic data 
Variable Zytux™  group (n=35) MabThera® group (n=35) 
B
as
el
in
e 
d
em
o
gr
ap
h
ic
 d
at
a 
Age (years) 57.94±8.44 59.24±8.16 
Sex (M/F) 28/7 29/6 
Weight (Kg) 71.06±11.40 69.45±11.47 
Body Mass Index (Kg/m2) 24.44±4.04 25.33±4.60 
Body Surface Area (m2) 1.83±0.16 1.78±0.16 
B
as
el
in
e 
la
b
o
ra
to
ry
 
d
at
a 
WBC × 103 (cells/mm3) 69.34±54.81 52.88±53.73 
Hb (g/dL) 12.05±2.18 12.20±2.45 
Plt  × 103 /microliter 128.63±66.55 139.40±52.54 
Lymphocyte % 84.07±14.56 77.67±13.27 
Reticulocyte × 106 /microliter 0.89±0.39 0.82±0.46 
SGOT (units/Liter) 20.41±7.33 19.22±5.71 
SGPT (units/Liter) 16.48±6.92 15.64±4.76 
ALKP (units/Liter) 226.40±80.78 224.26±73.45 
Creatinine (mg/dL) 1.06±0.23 1.11±0.22 
Bilirubin (mg/dL) 0.77±0.36 0.68±0.35 
D
is
ea
se
 
St
ag
in
g 
Binet stage 
Stage B 22 24 
Stage C 12 10 
 
Primary outcomes 
The ORR (CR + PR) as the primary end point was comparable between the treatment groups (88% and 89% for 
Zytux™ and MabThera®, respectively)(Table 3). 
 
Table 3: Clinical Response Rates 
Response Zytux™  group (n=25) MabThera® group (n=26) 95% confidence interval p-value 
Overall  22 (88%) 23 (89%) (-0.17,0.18) 0.96 
Complete 15 (60%) 15 (58%) (-0.29, 0.25) 0.87 
Partial  7 (28%) 8 (31%) (-0.22, 0.28) 0.83 
 
Secondary outcomes 
B-cell specific CD markers of interest analysis showed no 
statistically significant difference between the treatment 
groups. Peripheral blood lymphocyte counts dropped off 
significantly from baseline through chemotherapy cycles 
and remained comparable between treatment groups at 
each cycle and upon treatment completion( 
Figure 2, Figure 3). 
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Figure 2: Non-inferiority Forest Plot 
 
Figure 3.  Lymphocyte count and CD markers after four cycles 
 
 
 
 
Infusion reactions 
Incidence and type of infusion reactions occurred 
with Zytux™ were comparable to that of MabThera® 
(26% vs 20% for Zytux™ and MabThera®, 
respectively). The incidence of infusion reactions at 
first cycle was slightly higher with Zytux™ compared 
with MabThera® (26% vs. 14%). This trend did not 
achieve statistical significance and was not present 
at subsequent cycles (Table 4). The most frequent 
infusion reactions reported were shortness of 
breath (5 vs. 3), palpitation (3 vs. 3), rigors (3 vs. 3) 
and asthenia (3 vs.1) for Zytux™ and MabThera®, 
respectively. 
 
Table 4: Incidence of infusion-related reactions 
In
ci
d
en
ce
 
Infusion 
Cycle 
Zytux™  group 
(n=35) 
MabThera® group 
(n=35) 
Total 
First Cycle 9 (26%) 5 (14%) 14 (20%) 
Overall 9 (26%) 7 (20%) 
16 
(22.86%) 
 
Hematologic toxicities 
Summary of the hematologic toxicity analysis is 
presented in Table 5.  As shown, incidence of grade 
I thrombocytopenia was slightly higher for 
MabThera® group (non-significant); however, grade 
III and IV thrombocytopenia occurred more 
frequently in Zytux™ group. Seventy-nine events of 
any grade anemia were recorded, which were 
almost equally distributed in both groups. Thirty-
three and 36 events of neutropenia were observed 
in Zytux™ and MabThera® groups, respectively, 
although the rates of grade III/IV neutropenia were 
not significantly different between the two 
treatment groups. 
 
Table 5: Hematologic adverse reactions 
 
Zytux™ group 
(n=122) 
MabThera® group 
(n=115) 
Total p-value 
Thrombocytopenia No. (%) No. (%) No. (%)  
 Grade I (<LLN* to 75,000/mm3) 13 (11) 17 (15) 30 (13) 
 Grade II (50,000 to 75,000/mm3)  9 (7) 7 (6) 16 (7) 
 Grade III (25,000 to 50,000/mm3) 4 (3) 1 (1) 5 (2) 
 Grade IV (<25,000/mm3) 3 (2) 0 (0) 3 (1) 
 Total 29 (24) 25 (22) 54 (23) 0.18 
Anemia (Hemoglobin level)   
 Grade I (<LLN* to 10 g/dL) 18 (15) 18 (16) 36 (15) 
 Grade II (8.0 to 10.0 g/dL) 18 (15) 16 (14) 34 (14) 
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 Grade III (<8.0 g/dL) 5 (4) 4 (4) 9 (4) 
 Total 41 (34) 38 (33) 79 (33) 0.95 
Neutropenia   
 Grade I (<LLN* to 1500/mm3) 11 (9) 13 (11) 24 (10) 
 Grade II (1000 to 1500/mm3) 17 (14) 16 (14) 33 (14) 
 Grade III (500 to 1000/mm3) 4 (3) 6 (5) 10 (4) 
 Grade IV (<500/mm3) 1 (1) 1 (1) 2 (1) 
 Total 33 (27) 36 (31) 69 (30) 0.92 
* LLN: Lower Limit of Normal 
 
Non-hematologic toxicities 
Other adverse reactions observed in studied groups 
(other than infusion-related reactions) are 
presented in (Table 6). A total of 94 adverse 
reactions were observed during the scheduled 
chemotherapy cycles (47 in each group). The most 
prevalent adverse reactions were chills, nausea and 
hot flashes (observed 19, 13, and 8 times, 
respectively in total). There was one case of tumor 
lysis syndrome in MabThera® group. Results of liver 
enzyme analysis showed an incremental trend 
following chemotherapy administration, which 
were slightly lower for Zytux™ treated group, but 
neither the differences nor the increment were 
statistically significant. 
 
Table 6: Type of non-hematologic adverse reactions 
Type 
Zytux™ 
group 
(n=35) 
MabThera® 
group (n=35) 
Total 
Chills 
7 12 
19 
Nausea 
8 5 
13 
Hot flashes 
4 4 
8 
Weight loss 
4 1 
5 
Fever 
2 2 
4 
Infection 
3 1 
4 
Asthenia 
2 1 
3 
Shortness of Breath 
1 2 
3 
Pruritus 
1 2 
3 
Other* 
15 15 
30 
Other adverse reactions include reactions with occurrence of <5%. 
 
DISCUSSION 
   Based on efficacy and safety results of rituximab 
in different chemotherapy regimens, finding more 
available biosimilar medications could be helpful in 
reducing costs of therapy and enhancing more 
consequent treatments. New treatments for CLL are 
being developed, and targeted therapy is becoming 
more and more important. The role of CD20 
inhibitors must not be overlooked as drugs such as 
ofatumumab and obinutuzumab are recently 
approved by the FDA 17-22. Data from recent studies 
demonstrated that FCR regimen may result in 
higher complete response rates and also more 
prolonged duration from treatment to relapse in 
CLL patients 22. 
The primary outcome for which the non-inferiority 
margin was defined is ORR. The predefined margin 
for acceptable difference between treatment 
effects of Zytux™ and MabThera® was 20%. As the 
results of this study confirmed the efficacy of 
Zytux™ in terms of ORR, it was shown to be non-
inferior to MabThera® by the defined margin (Figure 
3). It is worth mentioning that the obtained results 
for ORR in our trial were in agreement with various 
studies in the literature in which the efficacy of 
rituximab was assessed along with FCR regimen and 
the response rate was cited 90-95% 11, 22, 23.  
As a secondary outcome, flow-cytometric assays on 
lymphocyte surface antigens of interest, including 
CD5, CD19, CD20 and CD22 demonstrated 
significant drop off in the percentage of cells 
expressing these antigens from baseline following 
administration of FCR regimen. The rates and 
magnitude of effects with Zytux™ resembled that of 
MabThera®, supporting the results obtained from 
the primary outcome.  
Infusion reactions are the most anticipated adverse 
reactions associated with rituximab administration, 
especially during the first cycle of treatment 12, 20, 24 
with the most reported being flu-like symptoms, 
chills and fever. It has been reported that infusion 
reactions occur in more than 50% of patients at 
early stages of the first cycle of infusion, but 
decrease in subsequent cycles 25-27. The rates 
reported in this trial were remarkably lower than 
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the literature, which could be due to exact 
implementation of infusion protocol and close 
monitoring applied in our setting. The most 
occurred reactions in the current study were chills, 
nausea and hot flashes. 
Hematologic adverse reactions induced by 
chemotherapy regimens are of particular 
importance as they are directly associated with 
patient’s quality of life and treatment outcomes. 
Regarding these facts, the safety profile of 
biosimilar products concerning hematologic 
toxicities needs to be closely considered. The results 
of the current study demonstrated that there were 
no statistically or clinically meaningful diversity 
between Zytux™ and MabThera® according to the 
hematologic toxicities. The hematologic events 
were in line with literature in terms of frequency 
and intensity 1, 27, and none of the events led to 
therapy discontinuation. 
The non-hematologic adverse reactions seen in this 
study were generally mild, except for one case of 
tumor lysis syndrome which occurred in MabThera® 
group, and also there was one case of 
hospitalization due to infection in Zytux™ group. In 
line with literature 12, 20, 23, 24, 28, the most common 
non-hematologic adverse reactions observed were 
chills, nausea, fatigue, pain and flu-like syndrome 
and, except for one case of tumor lysis syndrome, 
other events were mild to moderate, and no 
therapy interruptions were indicated. The profile of 
these reactions for Zytux™ were corresponding to 
that of MabThera®.  
The limitations of this study included small sample 
size and lack of survival information of patients 
because the complete follow-up was not 
performed. Furthermore, we only investigated the 
role of the biosimilar in CLL treatment. According to 
main guidelines, the efficacy or safety of biosimilar 
needs to be established in at least one of the 
indications to use it as a reference drug. 
 
 
CONCLUSION 
   According to the results of the current study, 
Zytux™ (Rituximab, AryoGen Pharmed) 
administration has been associated with 
comparable outcomes in terms of efficacy and 
adverse events in comparison to MabThera®, and as 
a result the non-inferiority of Zytux™ to MabThera® 
is established. 
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